ArticleJournal of virology2026
VP2-targeted sandwich ELISA (sELISA) enables direct detection of Senecavirus A (SVA).
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Senecavirus A (SVA) is an emerging swine virus that causes vesicular lesions clinically indistinguishable from other high-consequence transboundary viral vesicular diseases, creating significant diagnostic and economic challenges. Rapid and specific detection of SVA is, therefore, critical for supporting foreign animal disease (FAD) investigations. In this study, we generated and characterized monoclonal antibodies (MAbs) targeting the SVA VP2 capsid protein, and assessed their performance in multiple immunoassay formats. Two MAbs, 2D1 and 7B3, demonstrated strong and specific binding to both recombinant VP2 and native SVA. Using these antibodies, we developed a sandwich ELISA (sELISA) capable of direct viral detection with a sensitivity of 60 pg/mL. This assay detects contemporary SVA strains and provides a rapid, high-sensitivity platform suitable for differential disease diagnosis of idiopathic vesicular disease. These VP2-directed immunoassays offer valuable tools to enhance SVA surveillance and streamline FAD investigative workflows.IMPORTANCESenecavirus A (SVA) produces vesicular lesions that are clinically indistinguishable from foot-and-mouth disease and other high-consequence transboundary viruses, making rapid and accurate differentiation essential during foreign animal disease (FAD) investigations. These investigations impose substantial operational and economic burdens, including movement restrictions and diagnostic delays caused by the lack of rapid, field-deployable testing tools. Current surveillance relies heavily on laboratory-based molecular assays, underscoring the acute need for a rapid, pen-side method capable of direct SVA detection. The monoclonal antibodies developed in this study target conserved, surface-exposed VP2 on the SVA capsid, enabling the first sandwich ELISA capable of detecting native virus with high sensitivity across circulating strains. This diagnostic platform provides a fast, inexpensive tool with the potential to improve differential diagnosis, accelerate FAD investigations, and reduce the operational disruptions associated with SVA-related outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.